Prolonged total extracorporeal lung assistance without systemic heparinization. 1993

O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
Department of Anesthesia and Intensive Care, Landspitalinn National University Hospital, Reykjavik, Iceland.

A 16-year-old female developed severe ARDS in her single remaining lung following pneumonectomy for blunt trauma. Total extracorporeal lung assist (ECLA) for 40 days using a covalently heparin-coated circuit proved lifesaving. Systemic heparinization was not applied, as the heparinized surface by itself prevented clotting of the extracorporeal circuit. Systemic primary fibrinolysis developed but was not associated with major bleeding. A veno-right ventricular cannulation technique was used and maximum venous drainage for the extracorporeal circulation was achieved by elevating the bed 50 cm from the floor. This allowed extracorporeal blood flow (ECBF) approaching cardiac output (CO) and complete extracorporeal replacement of lung function. After 40 days, lung recovery allowed discontinuation of ECLA. Five days later the patient suffered serious lung collapse and was operated for a bronchopleural fistula. The patient was extubated 4 weeks after terminating ECLA and discharged in good condition 5 weeks later.

UI MeSH Term Description Entries
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015199 Extracorporeal Membrane Oxygenation Application of a life support system that circulates the blood through an oxygenating system, which may consist of a pump, a membrane oxygenator, and a heat exchanger. Examples of its use are to assist victims of SMOKE INHALATION INJURY; RESPIRATORY FAILURE; and CARDIAC FAILURE. ECMO Extracorporeal Membrane Oxygenation,Oxygenation, Extracorporeal Membrane,Venoarterial ECMO,Venoarterial Extracorporeal Membrane Oxygenation,Venovenous ECMO,Venovenous Extracorporeal Membrane Oxygenation,ECLS Treatment,ECMO Treatment,Extracorporeal Life Support,ECLS Treatments,ECMO Treatments,ECMO, Venoarterial,ECMO, Venovenous,Extracorporeal Life Supports,Extracorporeal Membrane Oxygenations,Life Support, Extracorporeal,Membrane Oxygenation, Extracorporeal,Treatment, ECLS,Treatment, ECMO,Venoarterial ECMOs,Venovenous ECMOs

Related Publications

O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
May 2006, Transplantation proceedings,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
October 1998, Artificial organs,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
August 1996, Pediatric surgery international,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
April 1994, Journal of cardiothoracic and vascular anesthesia,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
January 1966, Transactions - American Society for Artificial Internal Organs,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
November 2019, General thoracic and cardiovascular surgery,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
January 1980, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
October 1990, The International journal of artificial organs,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
January 1972, Transactions - American Society for Artificial Internal Organs,
O Fjalldal, and B Torfason, and P T Onundarson, and A Thorsteinsson, and G Vigfússon, and T Stefánsson, and V Magnússon
April 1991, The Journal of thoracic and cardiovascular surgery,
Copied contents to your clipboard!